Potassium iodide (KI) prophylaxis — the thyroid-blocking agent administered within 4 hours of radioactive iodine exposure preventing isotope uptake and reducing thyroid cancer risk by 90%+ — represents the fastest-growing application segment in the iodine deficiency drug market, with the Iodine Deficiency Drug Market reflecting KI emergency stockpiling as the geopolitical risk...
English
Arabic
French
Spanish
Portuguese
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek